Should You Buy Curis Inc (CRIS) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Sell
Latest Price
0.910
1 Day change
-0.55%
52 Week Range
3.570
Analysis Updated At
2026/01/28
CRIS is not a good buy right now for a beginner long-term investor with $50k–$100k who is impatient for an entry. The chart trend is still bearish (key moving averages stacked bearishly), recent fundamentals show widening losses and sharply weaker EPS/gross margin, and there are no Intellectia buy signals or near-term news catalysts to justify buying at the current ~$0.94 level.
Technical Analysis
Price/Trend: Bearish trend structure with SMA_200 > SMA_20 > SMA_5, signaling the longer-term downtrend remains intact.
Momentum: MACD histogram is positive (0.0131) but contracting, suggesting upside momentum is fading rather than strengthening. RSI_6 at 44.54 is neutral-to-weak (not oversold).
Levels: Pivot ~0.938 (price ~0.936 is sitting right at the pivot—indecisive). Near-term resistance at R1 ~1.014 (a break above would be needed to improve trend), support at S1 ~0.863 (next downside checkpoint).
Pattern-based short-horizon bias: Similar-candlestick stats imply mild downside bias over the next week (-1.68% expected).
Intellectia Proprietary Trading Signals
- [AI Stock Picker](module://ai_stock_pick): no signal on given stock today.
- [SwingMax](module://swingmax): No signal on given stock recently.
Options Data
Positive Catalysts
Revenue growth in 2025/Q3 (+8.36% YoY) shows some top-line expansion.
MACD remains slightly positive (trend could stabilize if price can reclaim and hold above ~1.01/R1).
No notable insider/hedge fund selling pressure indicated (both listed as Neutral).
Neutral/Negative Catalysts
Primary technical trend remains bearish (SMA_200 > SMA_20 > SMA_5) and momentum is not improving (MACD contracting).
2025/Q3 profitability deteriorated: net loss widened (Net Income -23.41% YoY) and EPS fell sharply (-71.18% YoY), which is unfavorable for long-term conviction.
Gross margin dropped materially (to 71.66, down -31.34% YoY), indicating weakening unit economics/quality of revenue.
No recent news catalyst in the past week to drive a reversal.
Analyst section data appears inconsistent (notes reference “Caris Life Sciences,” not Curis/CRIS), reducing confidence in using those ratings/targets for this ticker.
Financial Performance
Latest quarter: 2025/Q3. Revenue rose to 3,176,000 (+8.36% YoY), but growth quality weakened as losses expanded: Net Income fell to -7,729,000 (down -23.41% YoY), EPS declined to -0.49 (down -71.18% YoY), and Gross Margin decreased to 71.66 (down -31.34% YoY). Overall: top-line up, but profitability and margins deteriorated meaningfully.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
The provided analyst notes/price targets reference “Caris Life Sciences” with targets ranging roughly $28–$38 and mixed Hold/Buy/Outperform commentary; however, this appears to be a mismatch with the requested company (Curis Inc, CRIS). As a result, there is no reliable, usable trend in Wall Street ratings/targets for CRIS in the supplied data. Without valid coverage data, the pro case is unclear, and the cons (weak trend + deteriorating profitability) dominate.
Influential/political trading: No recent congress trading data available; hedge funds and insiders are marked Neutral with no significant recent trends.
Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 11 USD with a low forecast of 5 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast CRIS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CRIS is 11 USD with a low forecast of 5 USD and a high forecast of 17 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.916
Low
5
Averages
11
High
17
Current: 0.916
Low
5
Averages
11
High
17
Evercore ISI
Outperform
downgrade
$40 -> $38
AI Analysis
2026-01-05
Reason
Evercore ISI
Price Target
$40 -> $38
AI Analysis
2026-01-05
downgrade
Outperform
Reason
Evercore ISI lowered the firm's price target on Caris Life Sciences to $38 from $40 and keeps an Outperform rating on the shares. Recovering end markets and sector rotation have "set the stage for a 2026 Tools play," the analyst tells investors. In MedTech, the firm's survey work points to healthy procedure and CapEx trends into 2026 and early recovery signs in China support the group, but sector rotation and potential ACA and Medicare changes "have bears watching," the analyst added.
Canaccord
Kyle Mikson
Hold
maintain
$28 -> $30
2025-12-22
Reason
Canaccord
Kyle Mikson
Price Target
$28 -> $30
2025-12-22
maintain
Hold
Reason
Canaccord analyst Kyle Mikson raised the firm's price target on Caris Life Sciences to $30 from $28 and keeps a Hold rating on the shares. The firm previewed its life science tools and diagnostics covereage and believes momentum in the sector which began in the second half of this year, can be maintained in 2026. They beleve Caris Life Sciences could be attractive with continued momentum or a material share price pullback.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CRIS
